1. Medtech Insight
  2. >>Device Area
  3. >>Neurology

Medtronic’s Solitaire Gets STRATIS Real-World Stroke Boost

 
• By Reed Miller

Registry data presented at the International Stroke Conference confirm that mechanical thrombectomy with Medtronic’s Solitaire stent retriever can be safely performed in community hospitals as effectively as it was in the randomized trials observed in randomized trials. The results also show that the benefits of transferring a patient with an acute ischemic stroke to a comprehensive stroke center are usually not worth the extra time it takes to transport the patient there.

CT Scan-Brain_1200x675

Results from the STRATIS registry shows that community hospitals can treat acute stroke patients with mechanical thrombectomy using Medtronic PLC’s Solitaire stent retriever as effectively as comprehensive stroke centers at teaching hospitals. The study found that the benefits of transferring these patients to specialized centers is outweighed by the potential for additional brain damage that can result from the extra time it takes to get there.

STRATIS (Systematic Evaluation Of Patients Treated With Neurothrombectomy Devices For Acute Ischemic Stroke) is a prospective, multicenter single-arm registry designed...

More from Neurology

More from Device Area

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By Ashley Yeo

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 
• By Natasha Barrow

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.